http://www.zibb.com/all/theme/cq/ev3+Incorporated Zibb. The Global business search engine. en-US search@zibb.com (RB Search)Copyright (c) 2007 Reed Business Information. All rights reserved.Thu, 12 Mar 2009 00:00:00 GMTThu, 12 Mar 2009 00:00:00 GMT608831http://www.zibb.com/all/theme/cq/ev3+Incorporated http://www.zibb.com/images/en/g_zibb_logo_beta.gif http://www.bmocm.com/research/equities/us/researchnews/default.aspx?id=1004ev3 (EVVV) with a MARKET PERFORM rating. From Wuensch's note: "ev3 is a leader in the peripheral vascular (64% of total revenue) and neurovascular (31% of total revenue) markets, with one of the largest direct sales forces, and a broad product bag.http://www.bmocm.com/research/equities/us/researchnews/default.aspx?id=1004Ev3 IncorporatedThu, 12 Mar 2009 00:00:00 GMThttp://www.ev3.net/Robert Palmisano Appointed President, Chief Executive Officer and Director of ev3 Inc.http://www.ev3.net/Ev3 Incorporatedhttp://www.vertical-group.com/news-070704.htmPLYMOUTH, Minn. (July 7, 2004) - ev3 Inc., a privately held endovascular medical device company, has entered into a strategic distribution alliance with Invatec s.r.l., a privately held company in Brescia, Italy.http://www.vertical-group.com/news-070704.htmEv3 Incorporatedhttp://www.lurkertech.com/lg/ev3s.htmlEv3 is our name for a set of boards which identify themselves in the vl as "impact." As we will see later, cosmo2s also identify themselves in the VL as "impact." The ev3 boards all use the underlying design known as "Galileo 1.5" or "Impact Video.http://www.lurkertech.com/lg/ev3s.htmlEv3 Incorporatedhttp://www.newratings.com/headlines/EV3-Inc-_US26928A2006.htmlCopyright © 2002 - 2008 newratings.com GmbH | Legal | Licensing Quote data provided by IS.eFinance Solutions (powered by IS.Teledata AG) using StandardPoor's ComStock Inc. and others. Delay times are 15 mins for European exchanges and NASDAQ, 20 mins for NYSE and AMEX.http://www.newratings.com/headlines/EV3-Inc-_US26928A2006.htmlEv3 Incorporatedhttp://www.matrixone.com/matrixone/press_releases_20031117_ev3.htmlWestford, Mass. - November 17, 2003 - MatrixOne, Inc. (NASDAQ: MONE), a leading provider of collaborative product lifecycle management (PLM) solutions for the value chain, today announced that ev3 Inc.http://www.matrixone.com/matrixone/press_releases_20031117_ev3.htmlEv3 Incorporatedhttp://www.cheviotartus.co.uk/PEQs_PEQ/PEQs_PEQ_189.htmlNet Sales Grow by 60% Compared to Year-Ago Period PLYMOUTH, Minn., Jan. 9 /PRNewswire-FirstCall/ -- ev3 Inc. (Nasdaq: EVVV), a global endovascular device company, reported today net sales results for its fiscal fourth quarter ended December 31, 2005. (Logo: http://www.newscom.http://www.cheviotartus.co.uk/PEQs_PEQ/PEQs_PEQ_189.htmlEv3 Incorporatedhttp://www.pharmacychoice.com/News/article.cfm?Article_ID=46952The CREATE Trial enrolled 419 patients in 31 centers in a prospective, non- randomized study. The results of the CREATE trial compared favorably with performance criteria that were based on the results of previous carotid stenting trials.http://www.pharmacychoice.com/News/article.cfm?Article_ID=46952Ev3 Incorporatedhttp://www.researchandmarkets.com/reports/691205/ev3_inc_financial_and_strategic_analysis.pdfSummary ev3 Inc. (ev3) is a global medical device company engaged in developing catheter based or endovascular technologies for the minimally invasive treatment of vascular diseases and disorders. The company principally operates in United States, Canada and Europe.http://www.researchandmarkets.com/reports/691205/ev3_inc_financial_and_strategic_analysis.pdfEv3 Incorporatedhttp://www.minnesotabusiness.com/article.asp?articleID=1223&issueID=121ev3, Inc. [Emerging Companies, October 1997] received 510(k) clearance from the U. S. Food and Drug Administration for its Protege GPSSelf-Expanding Nitinol Stent in January. ev3 has received significant venture capital backing in recent months, enabling the company to acquire a St.http://www.minnesotabusiness.com/article.asp?articleID=1223&issueID=121Ev3 Incorporatedhttp://www.ipohome.com/common/ipoprofile.asp?ticker=EVVVProvides minimally-invasive medical devices for the treatment of vascular diseases.http://www.ipohome.com/common/ipoprofile.asp?ticker=EVVVEv3 Incorporatedhttp://www.biospace.com/news_story.aspx?StoryID=16499&full=1PLYMOUTH, Minn., April 25 /PRNewswire-FirstCall/ -- ev3 Inc. will release its 2006 first-quarter financial results on Tuesday, May 2, 2006, before regular market trading hours. (Logo: http://www.newscom.com/cgi-bin/prnh/20050615/CGEV3LOGO )http://www.biospace.com/news_story.aspx?StoryID=16499&full=1Ev3 Incorporatedhttp://www.micromedex.com/pressroom/news_feeds/?story_ID=37809&category=19Get the news that matters to you. Create your own customized news service that delivers the latest information directly to you. Plus you can view the most current press releases from Micromedex.http://www.micromedex.com/pressroom/news_feeds/?story_ID=37809&category=19Ev3 Incorporatedhttp://www.qad.com/portal/site/solutioncenter/menuitem.03e3ee31107469dc5ad066750690307a/?vgnextoid=da214813e08ba010VgnVCM100000810903a7RCRD&vgnextchannel=3d6764f648bcc010VgnVCM100000810903a7RCRDIn order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.http://www.qad.com/portal/site/solutioncenter/menuitem.03e3ee31107469dc5ad066750690307a/?vgnextoid=da214813e08ba010VgnVCM100000810903a7RCRD&vgnextchannel=3d6764f648bcc010VgnVCM100000810903a7RCRDEv3 Incorporatedhttp://www.holdrs.com/holdrs/main/index.asp?Action=Headlines&Description=&Image=TTH&symb=MDTCopyright © 2009 MarketWatch, Inc. All rights reserved. Please see our Terms of Use. MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc. Intraday data provided by Interactive Data Real-Time Services and subject to the Terms of Use.http://www.holdrs.com/holdrs/main/index.asp?Action=Headlines&Description=&Image=TTH&symb=MDTEv3 Incorporatedhttp://www.vertical-group.com/news-090803.htmNEW YORK, Sept. 8 /PRNewswire/ -- ev3 LLC, a new investment partnership controlled by Warburg Pincus, the global private equity firm, announced today that its holdings now include 100% of ev3 Inc. and approximately 70% of Micro Therapeutics, Inc. ev3 Inc.http://www.vertical-group.com/news-090803.htmEv3 Incorporatedhttp://www.vertical-group.com/news-070203.htmThe unique design of the Proxis Embolic Protection System allows it to provide complete embolic protection. The system is deployed in a proximal segment of the target vessel, upstream of the blockage. Therefore, there is no need to cross the blockage without first protecting the vessel.http://www.vertical-group.com/news-070203.htmEv3 Incorporatedhttp://www.ev3.net/index.asp?pageID=60We also invite you to visit our Investor Relations site for additional information on ev3.http://www.ev3.net/index.asp?pageID=60Ev3 Incorporatedhttp://www.ev3.net/index.asp?pageID=page_95.htmABOUT US INVESTOR RELATIONS EMPLOYMENT EVENTS CONTACT US EVENTS Calendar of Events There are currently no events scheduled. Please check back with us soon. ev3 Corporate World Headquarters Peripheral Vascular 9600 54th Avenue North Plymouth, MN 55442-2111 USA PH +1 763 398 7000 FX +1 763 398 7001http://www.ev3.net/index.asp?pageID=page_95.htmEv3 Incorporatedhttp://www.ev3.net/index.asp?pageID=page_59.htmWith a legacy in technology development and innovation, ev3 is helping endovascular specialists around the world perform more efficiently, effectively and predictably. ev3. Giving life to endovascular excellence.http://www.ev3.net/index.asp?pageID=page_59.htmEv3 Incorporatedhttp://www.ev3.net/index.asp?pageID=96&eventID=17ABOUT US INVESTOR RELATIONS EVENTS EMPLOYMENT CONTACT US Event Detail CX Vascular - Charing Cross 2006 Booth Number: 118 Date: April 8 - 11, 2006 Location: United Kingdom Registration: Back to events ev3 Corporate World Headquarters Cardio Peripheral Division 9600 54th Avenue North Plymouth, MNhttp://www.ev3.net/index.asp?pageID=96&eventID=17Ev3 Incorporatedhttp://www.ev3.net/index.asp?pageID=79&newsID=5PLYMOUTH, Minn. (July 7, 2004) ev3Inc., a privately heldendovascular medical device company, has enteredinto a strategicdistribution alliance with Invatec s.r.l., a privatelyheld company inBrescia, Italy.http://www.ev3.net/index.asp?pageID=79&newsID=5Ev3 Incorporatedhttp://www.ev3.net/index.asp?pageID=79&newsID=16, June 28, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- ev3 Inc. (Nasdaq: EVVV), a global endovascular device company, announced today that it has established a $37.http://www.ev3.net/index.asp?pageID=79&newsID=16Ev3 Incorporatedhttp://www.ev3.net/index.asp?pageID=79&newsID=23PLYMOUTH, Minn., Feb. 17 /PRNewswire-FirstCall/ -- ev3 Inc. (Nasdaq: EVVV) today announced the FDA 510(k) clearance of the SpideRX Embolic Protection Device for use in carotid artery stenting applications. ev3 is prepared to release the product immediately for commercial sale.http://www.ev3.net/index.asp?pageID=79&newsID=23Ev3 Incorporatedhttp://www.ev3.net/index.asp?pageID=79&newsID=48The SilverHawk(R) LS-M and MS-M with proprietary MEC(TM) Technology increases tissue collection capacity, representing an important advancement in Above the Knee treatment of Peripheral Artery Diseasehttp://www.ev3.net/index.asp?pageID=79&newsID=48Ev3 Incorporated